About US
Contact us
-
Generics drag AZ sales down by $1.35BAstraZeneca's second-quarter results continue the generics-are-woe trend in Big Pharma. This time, it's the antipsychotic drug Seroquel doing most of the damage. It fell over the patent cliff at the e2012/7/26
-
FDA to Congress: Agency not the cause of drug shortagesWhen it comes to drug shortages, the FDA says it is not the problem. It is part of the solution. That is what the agency says in a 9-page letter, with point-by-point refutations, to the ranking membe2012/7/25
-
Generics take a billion-dollar bite from Bristol-Myers salesIf today's pharma sales reports look grim, none is so grim as Bristol-Myers Squibb's ($BMY). The company's loss of exclusivity on its top-selling drug Plavix helped push U.S. sales down by 27%. The lo2012/7/25
-
Search for cheap prices sets stage for more counterfeit drugsAs Canadian online pharmacies morphed to protect their business model, they also became more vulnerable to counterfeits from places such as India and Turkey, where they turned for cheap supplies. That2012/7/24
-
J&J appeals $1.2B Risperdal marketing fineJohnson & Johnson has officially protested a $1.2 billion fine for mismarketing a blockbuster antipsychotic. In its ongoing fight against Risperdal marketing allegations, the company ($JNJ) app2012/7/24
-
Did anemia drug giants game the system to rake in billions?Amgen's big-selling anemia drugs were first brought in for questioning a few years ago. Studies and side-effect reports cast doubt on their safety. The FDA started a review. Then, in 2007, FDA slapped2012/7/23
-
SFDA Commissioner Yin Li meets WHO Regional Director for the Western Pacific Dr Shin Young-sooOn the morning of July 19, 2012, Yin Li, Commissioner of the State Food and Drug Administration (SFDA), met with Dr Shin Young-soo, WHO Regional Director for the Western Pacific, and his entourage. Ma2012/7/23
-
Next up for HIV prevention testing: Viiv's SelzentryTruvada may have been the first HIV fighter to be approved for prevention, but it may not be the last. Already, the National Institutes of Health has announced a study for another drug, Selzentry. So2012/7/20
-
New bill aims to mandate abuse-deterrent painkillersOn the heels of new addiction-fighting measures from FDA, Congressional reps are introducing a bill that would put the onus on drugmakers to curb abuse. The measure would require pain drugs to be form2012/7/20
-
J&J ramping up OTC production as 'decree' work allowsAlex Gorsky, in his first earnings call since taking the CEO spot at Johnson & Johnson ($JNJ), listed a lot of priorities--there is a lot to be fixed at the pharmaceutical and consumer products co2012/7/19